Sanofi, has announced a significant investment plan for its global capacity center (GCC) in Hyderabad, India. The company intends to invest $437 million in the facility by 2030, with an initial investment of $109 million planned for next year. This strategic move aims to expand the company’s operations and more than double its workforce in the region over the next two years.
The Hyderabad GCC is Sanofi’s largest such facility worldwide, currently employing 1,000 people. The company plans to increase this number to 2,600 by 2026, focusing on hiring data scientists and data engineers to bolster its digital team and enhance its artificial intelligence capabilities. This expansion highlights India’s growing importance in Sanofi’s global operations, with the Hyderabad staff working closely with stakeholders in the United States and France.
Madeleine Roach, executive vice president of Business Operations at Sanofi, emphasized the U.S. market’s confidence in the capabilities of the Hyderabad facility. The expanded Hyderabad center is expected to play a crucial role in handling documentation work related to drug clinical trials.
The investment aligns with broader industry trends; India’s domestic GCC market size to more than double to $110 billion by 2030. This growth is attributed to India’s skilled workforce and favorable business and policy environment. Additionally, Roach noted that geopolitical factors contribute to Sanofi’s focus on expanding in India, as pharmaceutical companies seek to diversify their operations and reduce dependence on China.
Sanofi’s investment in India reflects the country’s rising prominence in the global pharmaceutical and technology sectors. The move also underscores the growing trend of multinational companies establishing and expanding their global capacity centers in India to leverage the country’s talent pool and cost-effective operations, as well as capitalizing on India’s expanding role in the pharmaceutical industry’s global value chain.
